Neurology Articles

Neurology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ohashi W et al. - PGx enables earlier launch of a drug with less cost, representing benefit to pharmaceutical companies, patients and public as a whole. Currently, pharmaceutical companies are reluctant to introduce pharmacogenomics (PGx) in their practice, since cost–benefit of PGx is obscure and methodology to use PGx in drug development has not been fully established yet.

Related Articles

Pharmacogenomic perspectives on the management of mood disorders
Psychiatric Bulletin, 10/02/09    Relevance Score: 87%

Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia
Pediatric Blood & Cancer, 10/02/09    Relevance Score: 83%

Role of gut microbiota in Crohns disease
Expert Review of Gastroenterology & Hepatology, 10/13/09    Relevance Score: 80%

Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses Study
Pharmacotherapy, 10/07/09    Relevance Score: 80%

Pharmacogenomics: Personalizing Drug Therapy
American Journal of Nursing, 10/01/09    Relevance Score: 80%

Today in Economics of Medicine...keeping you current

Perception of the economic value of primary care services: A willingness to pay study
Health Policy, 12/03/09

Medicare Spending for Previously Uninsured Adults
Annals of Internal Medicine, 12/03/09

Public reporting and pay-for-performance programs in perioperative medicine
Cleveland Clinic Journal of Medicine, 12/02/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address